Development and Validation of an Immunoassay for Quantification of Topoisomerase I in Solid Tumor Tissues

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Pfister, Thomas D ^a   Hollingshead, Melinda ^b   Kinders, Robert J ^a   Zhang, Yiping ^a   Evrard, Yvonne A ^a   Ji, Jiuping ^a   Khin, Sonny A ^a   Borgel, Suzanne ^a   Stotler, Howard ^a   Carter, John ^a   Divelbiss, Raymond ^a   Kummar, Shivaani ^c   Pommier, Yves ^c   Parchment, Ralph E ^a   Tomaszewski, Joseph E ^c   Doroshow, James H ^c  

^a SAIC FREDERICK INC   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; INDENOISOQUINOLINE DERIVATIVE; ISOQUINOLINE DERIVATIVE; NSC 724998; TOPOTECAN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; COLON CANCER; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SOLID TUMOR; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR XENOGRAFT; VALIDATION PROCESS;

ANIMALS; BIOPSY; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; IMMUNOASSAY; ISOQUINOLINES; LEUKOCYTES, MONONUCLEAR; MICE; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; TIME FACTORS; TOPOISOMERASE I INHIBITORS; TOPOTECAN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 84871689343     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050494     Document Type: Article

References (49)

1. Nechiporchik N, Lieb K, Marquette L, Polin L, Peters GJ, et al. (2010) Preclinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers. Eur J Cancer Supplements 8: 64-64.
2. Pommier Y, (2009) DNA topoisomerase I inhibitors: Chemistry, biology, and interfacial inhibition. Chem Rev 109: 2894-2902.
3. Kummar S, Chen A, Ji JP, Zhang YP, Reid JM, et al. (2011) Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 71: 5626-5634.
4. Makeyev Y, Muggia FM, Rajan A, Giaccone G, Furuta T, et al. (2012) Topoisomerase I inhibitors: current use and prospects. In: Pommier Y, editor. DNA Topoisomerases and Cancer. New York: Springer. 245-277.
5. Teicher BA, (2008) Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 75: 1262-1271.
6. Pommier Y, Cushman M, (2009) The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol Cancer Ther 8: 1008-1014.
7. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, et al. (2008) Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial. J Clin Oncol 26: 2690-2698.
8. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, et al. (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370: 135-142.
9. Koopman M, Venderbosch S, van Tinteren H, Ligtenberg MJ, Nagtegaal I, et al. (2009) Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer 45: 1999-2006.
10. Ferrier CM, de Witte HH, Straatman H, van Tienoven DH, van Geloof WL, et al. (1999) Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. Br J Cancer 79: 1534-1541.
11. Yeh IT, (2002) Measuring HER-2 in breast cancer. Immunohistochemistry, FISH, or ELISA? Am J Clin Pathol 117Suppl: S26-35.
12. Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y, (1995) Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 55: 2116-2121.
13. Desai SD, Li T-K, Rodriguez-Bauman A, Rubin EH, Liu LF, (2001) Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 61: 5926-5932.
14. Desai SD, Mao Y, Sun MEI, Li T-K, Wu J, et al. (2000) Ubiquitin, SUMO-1, and UCRP in camptothecin sensitivity and resistance. Ann N Y Acad Sci 922: 306-308.
15. Desai SD, Zhang H, Rodriguez-Bauman A, Yang J-M, Wu X, et al. (2003) Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol Cell Biol 23: 2341-2350.
16. Devy J, Wargnier R, Pluot M, Nabiev I, Sukhanova A, (2004) Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines. Anticancer Res 24: 1745-1751.
17. Beidler DR, Cheng YC, (1995) Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol 47: 907-914.
18. Lin C-P, Ban Y, Lyu YL, Liu LF, (2009) Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks. J Biol Chem 284: 28084-28092.
19. Antony S, Agama KK, Miao ZH, Takagi K, Wright MH, et al. (2007) Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topolsomerase I cleavage complexes and overcome multidrug resistance. Cancer Res 67: 10397-10405.
20. Lin CP, Ban Y, Lyu YL, Desai SD, Liu LF, (2008) A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes. J Biol Chem 283: 21074-21083.
21. Li TK, Houghton PJ, Desai SD, Daroui P, Liu AA, et al. (2003) Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res 63: 8400-8407.
22. Burke TG, Mi Z, (1994) The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37: 40-46.
23. Pommier Y, (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789-802.
24. Urasaki Y, Laco G, Takebayashi Y, Bailly C, Kohlhagen G, et al. (2001) Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. Cancer Res 61: 504-508.
25. Kurtzberg LS, Battle T, Rouleau C, Bagley RG, Agata N, et al. (2008) Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors. Mol Cancer Ther 7: 3212-3222.
26. Sooryakumar D, Dexheimer TS, Teicher BA, Pommier Y, (2011) Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor genz-644282. Mol Cancer Ther 10: 1490-1499.
27. Antony S, Jayaraman M, Laco G, Kohlhagen G, Kohn KW, et al. (2003) Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: Base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Res. 63: 7428-7435.
28. DCTD Research Resources: Biomarkers Available:
29. Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, et al. (2010) Monitoring drug-induced γH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 16: 1073-1084.
30. Kinders RJ, Hollingshead M, Lawrence S, Ji J, Tabb B, et al. (2010) Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase inhibitor activity. Clin Cancer Res 16: 5447-5457.
31. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, et al. (2008) gammaH2AX and cancer. Nat Rev Cancer 8: 957-967.
32. Furuta T, Redon C, Pilch D, Sedelnikova O, Kohlhagen G, et al. (2002) ATR- and DNA-PK-dependent phosphorylation of histone H2AX by replication-mediated DNA double-strand breaks induced by camptothecin. Proc Am Assoc Cancer Res 43: 835.
33. Pfister TD, Reinhold WC, Agama K, Gupta S, Khin SA, et al. (2009) Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther 8: 1878-1884.
34. Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, et al. (2008) Preclinical modeling of a phase 0 clinical trial: Qualification of a pharmacodynamic assay of poly(ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res 14: 6877-6885.
35. Yu NY, Conway C, Pena RLS, Chen JY, (2007) STEALTH (R) liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models. Anticancer Res 27: 2541-2545.
36. Balasubramanian BN, Laurent DRS, Saulnier MG, Long BH, Bachand C, et al. (2004) Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-ben zo[b]-thienyl[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor model. J Med Chem 47: 1609-1612.
37. Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, et al. (1998) Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90: 505-511.
38. Fu Q, Kim SW, Chen HX, Grill S, Cheng YC, (1999) Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death. Mol Pharmacol 55: 677-683.
39. Liebes L, Potmesil M, Kim T, Pease D, Buckley M, et al. (1998) Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clin Cancer Res 4: 545-557.
40. Hsiang YH, Liu LF, (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722-1726.
41. Covey JM, Jaxel C, Kohn KW, Pommier Y, (1989) Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 49: 5016-5022.
42. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, et al. (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048.
43. Burgess DJ, Doles J, Zender L, Xue W, Ma B, et al. (2008) Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Nat Acad Sci U S A 105: 9053-9058.
44. Miao ZH, Player A, Shankavaram U, Wang YH, Zimonjic DB, et al. (2007) Nonclassic functions of human topoisomerase I: Genome-wide and pharmacologic analyses. Cancer Res 67: 8752-8761.
45. Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley MC (1997) Human tumor xenograft models in NCI drug development. In: Teicher BA, editor. Anticancer Drug Development Guide Preclinical Screening, Clinical Trials, and Approval. Totowa, NJ: Humana Press Inc. 101-125.
46. Hollingshead MG, Borgel SD, Carter J, Bonomi CA, Divelbiss R, et al. (2007) Evidence of in vivo efficacy for the indenoisoquinolones linked with pharmacodynamic markers for γH2AX. In: Proceedings for the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery B, and Clinical Applications, editor; 2007 October 22-26; San Francisco, CA. Abstract C18, 262.
47. Bookman MA, Malmström H, Bolis G, Gordon A, Lissoni A, et al. (1998) Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16: 3345-3352.
48. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, et al. (1992) Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10: 647-656.
49. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, et al. (2005) Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 11: 4338-4340.